To convert your AI ambitions into compounding enterprise value, biopharma leaders must shift from managing a collection of pilots to operating a disciplined portfolio system. This article explores Scimitar’s “AI Value Operating Flywheel,” outlining the structural decisions, governance archetypes, and strategic allocation variables required to ensure AI investments deliver measurable, long-term impact.
While many biopharma leaders have mastered the AI pilot, this article explores the three structural breaking points—data, culture, and ROI—that prevent “proofs of concept” from becoming enterprise-wide powerhouses.
This article provides a strategic framework for biopharma leaders to determine when to utilize deterministic rule-based automation versus probabilistic AI, evaluating five critical dimensions—accuracy, consistency, speed, judgment, and scale—to drive operational excellence while mitigating compliance risks in GxP environments.
This paper provides a strategic framework for life sciences decision-makers to evaluate and govern collaborations with AI-first startups, focusing on how these partnerships accelerate R&D discovery and create long-term differentiation in a complex regulatory landscape.
This article explores the emergence of AI-driven “Virtual Labs,” where autonomous agents simulate real-world research dynamics to dramatically accelerate drug discovery—a shift highlighted by a recent successful case of AI agents designing and validating new nanobodies for SARS-CoV-2.
This article examines the synergistic relationship between global regulatory harmonization, Real-World Evidence (RWE), and Artificial Intelligence, highlighting how standardized data frameworks enable AI to drive more accurate, evidence-based regulatory decisions.
This post discusses how Artificial Intelligence is revolutionizing global regulatory affairs by streamlining data analysis, optimizing drug discovery, and necessitating new frameworks to address the technical and ethical challenges of AI-driven decision-making.